Rezaei Shahabeddin, Shab-Bidar Sakineh, Abdulahi Abdurahman Ahmed, Djafarian Kurosh
Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Seizure. 2017 Feb;45:87-94. doi: 10.1016/j.seizure.2016.11.016. Epub 2016 Nov 24.
The objectives were to determine the influence of oxcarbazepine (OXC) monotherapy on the serum levels of total homocysteine (tHcy), vitamin B12 and folate in patient with epilepsy pooling together case-control or interventional studies. A comprehensive literature search was done through four databases including MEDLINE/PubMed, Scopus, Embase and Web of Science from January 2000 to February 2016. A random effects model (the DerSimonian-Laird estimator) was utilized to pool the effect sizes of the individual studies. The between-study variance was assessed using the Q2 test (significance level p<0.1) and quantified using the I test (>50% indicated evidence of heterogeneity). Overall, six studies found eligible for inclusion. The meta-analysis for tHcy revealed that the serum level of tHcy was no significant difference between patient on OXC monotherapy and healthy people [mean difference (MD) 0.31; 95% CI -1.05, 1.67, p=0.653]. The meta-analysis for vitamin B12 [MD -46.51; 95% CI -113.63, 20.62, p=0.174] and folate [MD -0.48; 95% CI -1.06, 0.11, p=0.113] indicated that there was no significant difference between patients on OXC monotherapy and healthy people. In conclusion, the meta-analysis does not support the hypotheses that OXC monotherapy changes the serum levels of tHcy, vitamin B12 and folate.
目的是通过汇总病例对照研究或干预性研究，确定奥卡西平（OXC）单药治疗对癫痫患者血清总同型半胱氨酸（tHcy）、维生素B12和叶酸水平的影响。通过四个数据库进行了全面的文献检索，包括2000年1月至2016年2月期间的MEDLINE/PubMed、Scopus、Embase和Web of Science。采用随机效应模型（DerSimonian-Laird估计量）汇总各研究的效应量。使用Q2检验（显著性水平p<0.1）评估研究间方差，并使用I检验（>50%表明存在异质性证据）进行量化。总体而言，六项研究符合纳入标准。tHcy的荟萃分析显示，接受OXC单药治疗的患者与健康人之间的血清tHcy水平无显著差异[平均差异（MD）0.31；95%置信区间-1.05，1.67，p=0.653]。维生素B12[MD -46.51；95%置信区间-113.63，20.62，p=0.174]和叶酸[MD -0.48；95%置信区间-1.06，0.11，p=0.113]的荟萃分析表明，接受OXC单药治疗的患者与健康人之间无显著差异。总之，荟萃分析不支持OXC单药治疗会改变血清tHcy、维生素B12和叶酸水平的假设。
